Immunomonitoring of Breast Cancer Patients During Systemic Treatment
Trial Parameters
Brief Summary
This study aims to constitute a most complete biological collection for patients treated for localized or metastatic breast cancer (in different cohorts depending on the type of systemic treatment received), in order to describe the basal immune response of patients treated for a breast cancer according to the stage of the disease, but above all to study how the different systemic treatments used in the management of breast cancer modulate this immune response.
Eligibility Criteria
Inclusion Criteria: 1. Woman aged between 18 and 85. 2. Patient with histologically proven infiltrating breast cancer. 3. Triple negative breast cancer or RH + / HER2- (OR and RP \<10% and HER2 negative (0 or 1+ in IHC or 2+ in IHC and FISH negative) 4. Patient receiving treatment corresponding to one of these cohorts: * In a metastatic situation with establishment of treatment with Paclitaxel regardless of the treatment line * In a metastatic situation with establishment of treatment with Epirubicin - cyclophosphamide (EC) regardless of the treatment line * In a metastatic situation with establishment of treatment with Eribulin regardless of the line of treatment * In a 1st line metastatic situation with initiation of treatment with Palbociclib or Abemaciclib, or Ribociclib in combination with hormone therapy (aromatase inhibitor) 5. Patient who signed the informed consent for the study. 6. Patient fit and able to adhere to protocol for the duration of the study, including visits, sch